FDA summary on Pfizer’s candidate COVID-19 vaccine supports earlier findings that it is safe and will prevent 95% of people from becoming sick.
Author: Karen Weintraub, USA TODAY
Continuing COVID-19 vaccine trials may put volunteers at unnecessary risk. Is that ethical?
The success of candidate vaccines by Pfizer/BioNTech and Moderna raises ethical questions about continuing placebo trials in which some may get sick.
Deliver a safe, effective COVID-19 vaccine in less than a year? Impossible. Meet Moncef Slaoui.
As science adviser of Operation Warp Speed, the veteran pharmaceutical executive helped usher a coronavirus vaccine to the US market in record time.
Moderna becomes second company to request emergency FDA authorization for COVID-19 vaccine candidate
Moderna will be the second coronavirus vaccine maker to request authorization from the government after similarly positive trial results for Pfizer.
Why this Harvard doctor is optimistic about US overcoming COVID-19 despite ‘epidemic of mistrust’
Paul Farmer has seen the effect of Haiti’s earthquake, Rwanda’s genocide and West Africa’s Ebola outbreak. They show how the US could handle COVID.
‘A new era’: Success of Pfizer and Moderna COVID-19 mRNA vaccines a major breakthrough
Coronavirus vaccines from Pfizer and Moderna are based on messenger RNA technology that could transform the way science fights diseases.
Infected again or endless COVID? How the ‘reinfection phenomenon’ could impact vaccines, herd immunity and human behavior.
Can you get it again? Scientists are still investigating to find out how long the immune system can keep someone safe from COVID-19 after infection.
Pfizer’s COVID-19 vaccine candidate shown to be 90% effective in early findings
Pfizer is the first drug company to release data from a large, Phase 3 trial, designed to show both effectiveness and safety.
Pfizer has expanded its COVID-19 vaccine trial to include teens. Some say it’s risky. Others argue it’s necessary.
After months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16.
COVID-19 vaccine should be ready for most vulnerable late this year, for everyone by spring, HHS Secretary Alex Azar says
During a rare CDC public briefing, HHS Secretary Alex Azar on Wednesday outlined a timeline for the COVID-19 vaccine and pledged it would be safe.